

**DOCKET NO.: ALLE0016-100 DIV  
(17510 DIV1)  
Serial No. 10/675,020**

**PATENT**

**Listing of Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-15 (Canceled)

16. (Original) A transdermal patch, comprising  
a pharmaceutical composition, which comprises:

a stabilized botulinum toxin; and

an enhancing agent that facilitates transdermal administration of the botulinum toxin in a bioactive form to a subdermal target site of a human patient without being administered to the patient's circulatory system; and

an adhesive disposed on one side of the transdermal patch to removably secure the patch on the patient's skin.

17. (Original) The transdermal patch of claim 16, wherein the adhesive is disposed around a depot containing the pharmaceutical composition.

18. (Original) The transdermal patch of claim 16, further comprising a plurality of needles extending from one side of the patch that is applied to the skin, wherein the needles extend from the patch to project through the stratum corneum of the skin without rupturing a blood vessel.

19. (Original) The transdermal patch of claim 18, wherein the botulinum toxin is provided in a depot in the patch so that pressure applied to the patch causes botulinum toxin to be directed through the needles and under the stratum corneum.

**DOCKET NO.: ALLE0016-100 DIV  
(17510 DIV1)  
Serial No. 10/675,020**

**PATENT**

20. (Original) The transdermal patch of claim 16, wherein the botulinum toxin is provided in a dry state in a plurality of wells, each of the wells covered by a membrane that is dissolvable with a fluid, and wherein the enhancing agent mixes with the botulinum toxin as the membrane over a well dissolves so that the absorption of the botulinum toxin is enhanced.

21. (Original) The transdermal patch of claim 16, wherein the botulinum toxin is botulinum toxin type A.

22-35. (Canceled)

36. (Previously presented) The transdermal patch of claim 16, wherein the enhancing agent comprises 1 part water, 1 part ethanol, and 1 part polyethylene glycol.

37. (Previously presented) The transdermal patch of claim 36 wherein the ethanol is 90% ethanol.

38. (Previously presented) The transdermal patch of claim 16, wherein the enhancing agent comprises 1 part of 10% transfersomes and 0.9 part of a buffer.

39. (Previously presented) A transdermal patch, comprising  
a pharmaceutical composition, which comprises:

    a stabilized botulinum toxin; and

    an enhancing agent that facilitates transdermal administration of the botulinum toxin in a bioactive form to a subdermal target site of a human patient; and

    an adhesive disposed on one side of the transdermal patch to removably secure the patch on the patient's skin.

**DOCKET NO.: ALLE0016-100 DIV  
(17510 DIV1)  
Serial No. 10/675,020**

**PATENT**

40. (Previously presented) The transdermal patch of claim 39, wherein less than 25% of the administered botulinum toxin permeates into a blood vessel.

41. (Previously presented) The transdermal patch of claim 39, wherein the enhancing agent comprises 1 part water, 1 part ethanol, and 1 part polyethylene glycol.

42. (Previously presented) The transdermal patch of claim 39 wherein the ethanol is 90% ethanol.

43. (Previously presented) The transdermal patch of claim 39, wherein the enhancing agent comprises 1 part of 10% transfersomes and 0.9 part of a buffer.

44. (Previously presented) The transdermal patch of claim 39, wherein the botulinum toxin is botulinum toxin type A.